Search results for: treatment
Gene Replacement Therapy for CMT4A Neuropathy in Rodents
With CMTA support of $248,950, researchers at the University of Texas Southwestern, led by CMTA’s...
CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
CMTA honors the life and legacy of Dr. M. Laura Feltri, Scientific Advisory Board member, visionary CMT researcher, and cherished friend to the community.
Development of a Human-Derived Myelin-Containing Organoid as a Reference Model for CMT1A
With CMTA support, researchers at the University of Antwerp, led by Vincent Timmerman, PhD, are...
Gene Editing Strategies for Demyelinating CMT
With CMTA support of $448,748, researchers are advancing CRISPR-based genetic therapies to address CMT1A and...
ASO Approaches for CMT2E
With CMTA support of $225,483, researchers at the University of Miami, led by CMTA Strategy...
Testing New UPR-Targeted Therapies for CMT1B
Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Milan, Italy, supported by the...
Hereditary Sensory Neuropathy Serine Trial (SENSE Trial)
With CMTA support of $354,826, researchers at the UCL Queen Square Institute of Neurology in...
Schwann Cell-Targeted Gene Therapy Approaches to Treat CMT1A and Other Demyelinating Neuropathies
With CMTA support of over $160,000, an international team of researchers is developing genetic therapy...
Applied Therapeutics – INSPIRE
This study is designed to assess the efficacy and safety of AT-007 treatment in patients...
Development of a new CMT1A research toolbox: an alternative human stem cell-based strategy
With CMTA support of $98,890, researchers at Hasselt University in Belgium, led by Esther Wolfs,...
